New Drugs and Clinical Trials · us
FDA Approves First Drug Specifically for Primary Membranous Nephropathy: Gazyva Improves Complete Remission Rates at Two Years
The anti-CD20 antibody offers a new option for adults at risk of disease progression. The trial showed a higher rate of complete remission of proteinuria than tacrolimus, but evidence remains limited on whether it can further slow kidney function decline.
When the immune system attacks the kidneys’ filtration barrier, proteins that should remain in the blood leak into the urine, and patients may gradually develop declining kidney function. For primary membranous nephropathy, the United States now has its first specifically approved treatment: the U.S. Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab) to induce remission of proteinuria in adults at risk of disease progression.
Primary membranous nephropathy is a rare autoimmune kidney disease that damages the glomeruli, which filter the blood. Substantial protein loss may be accompanied by severe swelling, fatigue, and other complications. Obinutuzumab is a monoclonal antibody targeting CD20 that acts on the abnormal immune response by depleting B cells carrying this marker; this approval extends its use to another immune-related kidney disease.
The phase 3 MAJESTY trial supporting the approval enrolled 142 adults and used a randomized, open-label, multicenter design to compare obinutuzumab with the immunosuppressant tacrolimus. The latter was already used off-label for this disease. The trial followed patients through week 104, primarily assessing whether they achieved complete remission of proteinuria without receiving rescue therapy, experiencing treatment failure, or withdrawing early from the trial.
“Complete remission” had a defined threshold: a urine protein-to-creatinine ratio no greater than 0.3 g/g, with a stable estimated glomerular filtration rate (eGFR). The FDA reported that 36% and 6% of patients in the respective groups met this threshold. When Genentech announced priority review in July, it reported figures of 36.9% and 5.7%, with an adjusted difference of 31.1 percentage points. Although the figures in the two reports differ slightly, both support the superiority of obinutuzumab over tacrolimus on the primary endpoint.
The advantage in proteinuria remission must still be considered separately from long-term protection of kidney function. According to HCPLive’s summary, the trial endpoint of a “sustained decline in eGFR of at least 30%” did not reach statistical significance. Under the prespecified hierarchical testing sequence, subsequent endpoints, including duration of remission and improvement in fatigue, could therefore no longer formally be claimed to be statistically significant. A higher complete remission rate thus cannot currently be interpreted directly as proof of reduced kidney failure.
Safety is also part of the treatment trade-off. HCPLive reported that rates of grade 3 or higher adverse events were 22% and 19% in the obinutuzumab and tacrolimus groups, respectively, while serious adverse event rates were 17% and 14%; these figures alone are insufficient to establish that the two treatments have equivalent safety. The FDA noted that common side effects in the trial included infusion-related reactions and upper respiratory tract infections, and the drug’s labeling retains boxed warnings for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.
This development has progressed from priority review in July to formal approval, establishing a treatment option supported by clinical trial evidence for certain adult patients. However, MAJESTY was limited in size, was not blinded, and used only tacrolimus as a comparator; its results cannot yet answer how obinutuzumab compares with all existing treatment strategies. Longer-term follow-up will help clarify how long proteinuria remission lasts and whether it translates into more durable protection of kidney function.